The impact of bone metastases and SREs

Skeletal complications associated with bone metastases can increase the risk of mortality.

Learn more >

Aromatase inhibitors (Als) improve disease-free survival but increase bone loss

Women with breast cancer who are taking Al therapy have an increased fracture risk.

Learn more >

RANK Ligand and the biology of bone destruction

RANK Ligand is key to the development and activation of osteoclasts and plays a key role in bone loss.

Watch the video >
References:
  1. Mundy GR. Nature Rev Cancer. 2002;2:584-593.
  2. Roodman GD. N Engl J Med. 2004;350:1655-1664.
  3. Boyle WJ, et al. Nature. 2003;423:337-342.
  4. Fuller K, et al. J Exp Med. 1998;188:997-1001.
  5. Lacey DL, et al. Am J Pathol. 2000;157:435-448.
  6. O'Brien EA, et al. Biochem Biophys Res Commun. 2000;274:281-290.
  7. Huber DM, et al. Endocrinology. 2001;142:3800-3808.
  8. Yasuda H, et al. Proc Natl Acad Sci USA. 1998;95:3597-3602.
  9. Hofbauer LC, et al. JAMA. 2004;292:490-495.
This site is intended for use by US Healthcare Professionals only

© 2009 Amgen Inc. All Rights Reserved.

This Web site is intended to be an educational resource only. It is not intended or deemed to be a directive or guidance regarding clinical practice, which is solely the responsibility of the treating physician.

Amgen Inc. disclaims any liability or damages arising from any errors or use of this information.